Minimal uterine serous carcinoma: Current concepts in diagnosis and prognosis

Pathology

Volumn 39, Issue 1, 2007, Pages 125-133

  Rabban, Joseph T ^a   Zaloudek, Charles J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Endometrial intraepithelial carcinoma; Minimal uterine serous carcinoma; p53

Indexed keywords

PROTEIN P53;

ARTICLE; BENIGN TUMOR; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER INVASION; CANCER STAGING; CELL STRUCTURE; CLEAR CELL CARCINOMA; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; ENDOMETRIOID CARCINOMA; ENDOMETRIOSIS; ENDOMETRIUM CARCINOMA; GENE MUTATION; HUMAN; HYSTERECTOMY; METAPLASIA; MYOMETRIUM; POLYPECTOMY; PRECANCER; PROGNOSIS; RECURRENCE RISK; TUMOR BIOPSY; TUMOR LOCALIZATION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERUS BIOPSY; UTERUS CARCINOMA;

CARCINOMA IN SITU; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; PROGNOSIS; UTERINE NEOPLASMS;

EID: 33847176267     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020601146814     Document Type: Article

References (49)

1. Cullen TS. Cancer of the Uterus: Its Pathology, Symptomatology, Diagnosis, and Treatment. New York: D Appleton and Company, 1990.
2. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004; 444: 213-23.
3. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10-7.
4. Silverberg SG, Kurman RJ, Nogales F, Mutter GL, Kubick-Huch RA, Tavassoli FA. Tumors of the Uterine Corpus. In: Tavassoli FA, Devilee P, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press, 2003.
5. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995; 26: 1260-7.
6. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992; 16: 600-10.
7. Spiegel GW. Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol 1995; 19: 417-32.
8. Hui P, Kelly M, O'Malley DM, Tavassoli F, Schwartz PE. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Mod Pathol 2005; 18: 75-82.
9. Wheeler DT, Bell KA, Kurman RJ, Sherman ME. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol 2000; 24: 797-806.
10. Carcangiu ML, Tan LK, Chambers JT. Stage IA uterine serous carcinoma: a study of 13 cases. Am J Surg Pathol 1997; 21: 1507-14.
11. Soslow RA, Pirog E, Isacson C. Endometrial intraepithelial carcinoma with associated peritoneal carcinomatosis. Am J Surg Pathol 2000; 24: 726-32.
12. Zheng W, Khurana R, Farahmand S, Wang Y, Zhang ZF, Felix JC. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am J Surg Pathol 1998; 22: 1463-73.
13. Silverberg SG, Kurman RJ, Nogales F, Mutter GL, Kubick-Huch RA, Tavassoli FA. Tumors of the Uterus. In: Tavassoli FA, Devilee P, editors. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon: IARC Press, 2003; 225.
14. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997; 150: 177-85.
15. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol 1992; 47: 298-305.
16. Baergen RN, Warren CD, Isacson C, Ellenson LH. Early uterine serous carcinoma: clonal origin of extrauterine disease. Int J Gynecol Pathol 2001; 20: 214-9.
17. Dietrich CS, III, Modesitt SC, DePriest PD, et al. The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Gynecol Oncol 2005; 99: 557-63.
18. Kelly MG, O'Malley DM, Hui P, et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol 2005; 98: 353-9.
19. Acs G, Pasha T, Zhang PJ. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 2004; 23: 110-8.
20. McCluggage WG. WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int J Gynecol Pathol 2004; 23: 97-9.
21. Shimizu M, Toki T, Takagi Y, Konishi I, Fujii S. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 2000; 19: 158-63.
22. Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 2004; 44: 109-15.
23. Egan JA, Ionescu MC, Eapen E, Jones JG, Marshall DS. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Int J Gynecol Pathol 2004; 23: 119-22.
24. Schedl A, Hastie N. Multiple roles for the Wilms' tumour suppressor gene, WT1 in genitourinary development. Mol Cell Endocrinol 1998; 140: 65-9.
25. Gray CA, Bartol FF, Tarleton BJ, et al. Developmental biology of uterine glands. Biol Reprod 2001; 65: 1311-23.
26. Euscher ED, Malpica A, Deavers MT, Silva EG. Differential expression of WT-1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps. Am J Surg Pathol 2005; 29: 1074-8.
27. Kupryjanczyk J, Thor AD, Beauchamp R, Poremba C, Scully RE, Yandell DW. Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease. Mod Pathol 1996; 9: 166-73.
28. Demopoulos RI, Mesia AF, Mittal K, Vamvakas E. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis. Int J Gynecol Pathol 1999; 18: 233-7.
29. Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation. Hum Pathol 1998; 29: 924-31.
30. Zheng W, Cao P, Zheng M, Kramer EE, Godwin TA. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 1996; 61: 167-74.
31. Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol 1998; 29: 551-8.
32. Hendrickson MR, Kempson RL. Endometrial epithelial metaplasias: proliferations frequently misdiagnosed as adenocarcinoma. Report of 89 cases and proposed classification. Am J Surg Pathol 1980; 4: 525-542.
33. Quddus MR, Sung CJ, Zheng W, Lauchlan SC. p53 immunoreactivity in endometrial metaplasia with dysfunctional uterine bleeding. Histopathology 1999; 35: 44-9.
34. Arias-Stella J. The Arias-Stella reaction: facts and fancies four decades after. Adv Anat Pathol 2002; 9: 12-23.
35. Vang R, Barner R, Wheeler DT, Strauss BL. Immunohistochemical staining for Ki-67 and p53 helps distinguish endometrial Arias-Stella reaction from high-grade carcinoma, including clear cell carcinoma. Int J Gynecol Pathol 2004; 23: 223-33.
36. Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 2006; 19: 1091-100.
37. Cina SJ, Richardson MS, Austin RM, Kurman RJ. Immunohistochemical staining for Ki-67 antigen, carcinoembryonic antigen, and p53 in the differential diagnosis of glandular lesions of the cervix. Mod Pathol 1997; 10: 176-80.
38. McCluggage G, McBride H, Maxwell P, Bharucha H. Immunohistochemical detection of p53 and bcl-2 proteins in neoplastic and non-neoplastic endocervical glandular lesions. Int J Gynecol Pathol 1997; 16: 22-7.
39. Leary J, Jaworski R, Houghton R. In-situ hybridization using biotinylated DNA probes to human papillomavirus in adenocarcinoma-in-situ and endocervical glandular dysplasia of the uterine cervix. Pathology 1991; 23: 85-9.
40. Tase T, Okagaki T, Clark BA, Twiggs LB, Ostrow RS, Faras AJ. Human papillomavirus DNA in adenocarcinoma in situ, microinvasive adenocarcinoma of the uterine cervix, and coexisting cervical squamous intraepithelial neoplasia. Int J Gynecol Pathol 1989; 8: 8-17.
41. Baker PM, Clement PB, Bell DA, Young RH. Superficial endometriosis of the uterine cervix: a report of 20 cases of a process that may be confused with endocervical glandular dysplasia or adenocarcinoma in situ. Int J Gynecol Pathol 1999; 18: 198-205.
42. Nezhat F, Cohen C, Rahaman J, Gretz H, Cole P, Kalir T. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts. Cancer 2002; 94: 2935-40.
43. Nezhat FR, Kalir T. Comparative immunohistochemical studies of endometriosis lesions and endometriotic cysts. Fertil Steril 2002; 78: 820-4.
44. Schneider J, Jimenez E, Rodriguez F, del Tanago JG. c-myc, c-erb-B2, nm23 and p53 expression in human endometriosis. Oncol Rep 1998; 5: 49-52.
45. Oliva E, Clement PB, Young RH. Tubal and tubo-endometrioid metaplasia of the uterine cervix. Unemphasized features that may cause problems in differential diagnosis: a report of 25 cases. Am J Clin Pathol 1995; 103: 618-23.
46. Suh KS, Silverberg SG. Tubal metaplasia of the uterine cervix. Int J Gynecol Pathol 1990; 9: 122-8.
47. Nucci MR, Young RH. Arias-Stella reaction of the endocervix: a report of 18 cases with emphasis on its varied histology and differential diagnosis. Am J Surg Pathol 2004; 28: 608-12.
48. McCluggage WG, Sumathi VP, McManus DT. Uterine serous carcinoma and endometrial intraepithelial carcinoma arising in endometrial polyps: report of 5 cases, including 2 associated with tamoxifen therapy. Hum Pathol 2003; 34: 939-43.
49. Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks CB. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol 2004; 23: 129-37.